Nasdaq · CIK 0001781983
APRE Aprea Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Mar 31, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
4
with a Form 4 at this company
Signals
Open-market buys and sells at Aprea Therapeutics, Inc., scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 20Weak | sell | Duey Marc director | $30k | 6,462 | -3% | - | |
| 40Moderate | buy 4 | Gilad Oren President/CEO | $1,958 | 500 | +0% | - | |
| 49Moderate | buy 4 | Duey Marc director | $132k | 30,000 | +14% | - | |
| 37Weak | buy 4 | Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | $123 | 50 | +0% | - | |
| 25Weak | buy 4 | Duey Marc director | $490 | 190 | +0% | - | |
| 40Moderate | buy 4 | Gilad Oren President/CEO | $725 | 250 | +0% | - | |
| 37Weak | buy 4 | Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | $1,175 | 450 | +2% | - | |
| 35Weak | buy 4 | Gilad Oren President/CEO | $2,971 | 1,150 | +0% | - | |
| 41Moderate | buy 4 | Seizinger Bernd R. director | $27k | 10,000 | +29% | - |
Transactions
The last 14 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 27, 2025 | Gilad Oren President/CEO | AGrant or award Common Stock | +6,725 | $0.00 | $0 | 340,120 | Mar 31, 2025 |
| Mar 27, 2025 | Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | AGrant or award Common Stock | +3,365 | $0.00 | $0 | 22,733 | Mar 31, 2025 |
| Mar 27, 2025 | Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | AGrant or award Stock Options (Right to Buy)derivative | +13,460 | $0.00 | $0 | 13,460 | Mar 31, 2025 |
| Mar 27, 2025 | Gilad Oren President/CEO | AGrant or award Stock Options (Right to Buy)derivative | +26,900 | $0.00 | $0 | 26,900 | Mar 31, 2025 |
| Oct 18, 2024 | Duey Marc director | SOpen-market sale Common Stock | -6,462 | $4.58 | $30k | 233,651 | Oct 25, 2024 |
| Oct 23, 2024 | Gilad Oren President/CEO | POpen-market purchase Common Stock | +500 | $3.92 | $1,958 | 333,395 | Oct 24, 2024 |
| Oct 16, 2024 | Duey Marc director | POpen-market purchase Common Stock | +30,000 | $4.39 | $132k | 240,113 | Oct 17, 2024 |
| Oct 15, 2024 | Gilad Oren President/CEO | POpen-market purchase Common Stock | +250 | $2.90 | $725 | 332,895 | Oct 16, 2024 |
| Oct 14, 2024 | Duey Marc director | POpen-market purchase Common Stock | +190 | $2.58 | $490 | 210,113 | Oct 16, 2024 |
| Oct 11, 2024 | Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | POpen-market purchase Common Stock | +50 | $2.46 | $123 | 19,368 | Oct 16, 2024 |
| Oct 11, 2024 | Seizinger Bernd R. director | POpen-market purchase Common Stock | +10,000 | $2.68 | $27k | 44,730 | Oct 15, 2024 |
| Oct 10, 2024 | Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | POpen-market purchase Common Stock | +450 | $2.61 | $1,175 | 19,318 | Oct 15, 2024 |
| Oct 10, 2024 | Gilad Oren President/CEO | POpen-market purchase Common Stock | +150 | $2.54 | $381 | 331,645 | Oct 15, 2024 |
| Oct 14, 2024 | Gilad Oren President/CEO | POpen-market purchase Common Stock | +1,000 | $2.59 | $2,590 | 332,645 | Oct 15, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Duey Marcdirector
- Gilad OrenPresident/CEO
- Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr
- Seizinger Bernd R.director
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.